Octane joins forces with Aesculap to advance living-tissue orthopedic
implants into clinical use
Kingston, Ontario, May 2012 – Octane Medical Group has entered into a partnership with Aesculap Biologics, LLC, a subsidiary of the multinational Aesculap Inc., (a B. Braun company) one of the world’s largest orthopedic companies with a focus on innovative spine and orthopedic treatments.
The partnership is an important step forward in Octane and Aesculap’s goal of bringing automated production of living-tissue orthopedic implants into clinical use on a global scale, says Tim Smith, CEO of Octane Medical Group. The biological properties of these living implants allow for integration into the implant site to accelerate healing with minimal risk of biological rejection and subsequent revision surgery.
The living implants are now in clinical trials focusing on knee cartilage injuries.
For press inquiries please contact Renee Thibodeau.
About Octane Technology
Cocoon™ is a patient-scale cell therapy system that forms the core of a series of versatile cell and tissue therapy production systems. Unlike other bioreactor systems, this platform integrates multiple steps, including upstream and downstream processing. From cell source isolation and cell expansion, through to cell collection, cell washing and final product formation – all in a closed, single-use disposable cassette
Coupled with advanced bioreactors, biosensor feedback and innovative cell scaffolds, this cell culture and tissue engineering platform opens up an array of clinical applications. Cocoon is an integrated turnkey production solution that can be configured as a compact but powerful system with a small footprint, or as a multi-patient system for ultra-efficient, enterprise-level deployment. Please read more about our game-changing innovations in regenerative medicine .